Viamet Pharmaceuticals Secures $12,000,014 New Funding

  • Feed Type
  • Date
  • Company Name
    Viamet Pharmaceuticals
  • Mailing Address
    4505 Emperor Blvd. Durham, NC 27703 USA
  • Company Description
    Viamet Pharmaceuticals discovers and develops best-in-class inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, our Metallophile Technology.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    Proceeds purposes were not disclosed. 12 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.
  • M&A Terms
  • Venture Investor

Trending on Xconomy